Michael Charlton

机构：University of Chicago, Madrigal Pharmaceuticals (United States) · ORCID：0000-0002-8766-7494

发表论文 402 篇 · 总被引 43553 次 · h-index 93

代表论文

• Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis (2024 · Clinical Gastroenterology and Hepatology · 被引 160)
• The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists (2025 · Expert Opinion on Investigational Drugs · 被引 29)
• Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 27)
• Current Burden of and Geographic Disparities in Liver Mortality and Access to Liver Transplant (2024 · JAMA Network Open · 被引 17)
• Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis (2025 · Journal of Gastroenterology · 被引 15)
• LBO-002 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis (2025 · Journal of Hepatology · 被引 9)